No elevated genomic damage in children and adolescents with attention deficit/hyperactivity disorder after methylphenidate therapy

Toxicology Letters

Volumn 184, Issue 1, 2009, Pages 38-43

  Walitza, Susanne ^a,b   Kämpf, Kristina ^a   Artamonov, Natalia ^a   Romanos, Marcel ^a   Gnana Oli, Rajaraman ^a   Wirth, Susanne ^a   Warnke, Andreas ^a   Gerlach, Manfred ^a   Stopper, Helga ^a  

^a UNIVERSITY OF WÜRZBURG   (Germany)

^b UNIVERSITY OF ZURICH   (Switzerland)

Author keywords

ADHD; Cytogenetic effects; Methylphenidate; Micronuclei; Psychostimulants

Indexed keywords

ATOMOXETINE; METHYLPHENIDATE; RISPERIDONE; SULTIAME;

ADOLESCENT; ARTICLE; ATTENTION DEFICIT DISORDER; BLOOD SAMPLING; CHEEK MUCOSA; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; GENETIC DAMAGE; GENOME; HUMAN; HUMAN CELL; LYMPHOCYTE; MICRONUCLEUS; PRIORITY JOURNAL; SIDE EFFECT;

ADOLESCENT; ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; CASE-CONTROL STUDIES; CENTRAL NERVOUS SYSTEM STIMULANTS; CHILD; CHILD, PRESCHOOL; DNA DAMAGE; FEMALE; HUMANS; MALE; METHYLPHENIDATE; MICRONUCLEUS TESTS; MOUTH MUCOSA;

EID: 57649219000     PISSN: 03784274     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.toxlet.2008.10.011     Document Type: Article

References (27)

1. Achenbach T., and Rescorla L. Manual for the Child Behavior Checklist (2001), University of Vermont, Department of Psychiatry, Burlington, VT pp. 6-18
2. Baier G., Stopper H., Kopp C., Winkler U., and Zwirner-Baier I. Respiratory diseases and genotoxicity in tobacco smoke exposed children. Laryngorhinootologie 81 (2002) 217-225
3. Benzie I.F., and Strain J.J. The ferric reducing ability of plasma (FRAP) as a measure of "antioxidant power": the FRAP assay. Anal. Biochem. 239 (1996) 70-76
4. Biederman J., and Faraone S.V. Attention-deficit hyperactivity disorder. Lancet 366 (2005) 237-248
5. Bonassi S., Fenech M., Lando C., Lin Y.P., Ceppi M., Chang W.P., Holland N., Kirsch-Volders M., Zeiger E., Ban S., Barale R., Bigatti M.P., Bolognesi C., Jia C., Di Giorgio M., Ferguson L.R., Fucic A., Lima O.G., Hrelia P., Krishnaja A.P., Lee T.K., Migliore L., Mikhalevich L., Mirkova E., Mosesso P., Müller W.U., Odagiri Y., Scarffi M.R., Szabova E., Vorobtsova I., Vral A., and Zijno A. Human MicroNucleus project: international database comparison for results with the cytokinesis-block micronucleus assay in human lymphocytes. I. Effect of laboratory protocol, scoring criteria, and host factors on the frequency of micronuclei. Environ. Mol. Mutagen. 37 (2001) 31-45
6. Bonassi S., Znaor A., Ceppi M., Lando C., Chang W.P., Holland N., Kirsch-Volders M., Zeiger E., Ban S., Barale R., Bigatti M.P., Bolognesi C., Cebulska-Wasilewska A., Fabianova E., Fucic A., Hagmar L., Joksic G., Martelli A., Migliore L., Mirkova E., Scarfi M.R., Zijno A., Norppa H., and Fenech M. An increased micronucleus frequency in peripheral blood lymphocytes predicts the risk of cancer in humans. Carcinogenesis 28 (2007) 625-631
7. DSM-IV-TR. Diagnostic and Statistical Manual of Mental Disorders. 4th ed.: Text Revision (2000), American Psychiatric Association, Washington, DC
8. El-Zein R.A., Abdel-Rahman S.Z., Hay M.J., Lopez M.S., Bondy M.L., Morris D.L., and Legator M.S. Cytogenetic effects in children treated with methylphenidate. Cancer Lett. 230 (2005) 284-291
9. El-Zein R.A., Hay M.J., Lopez M.S., Bondy M.L., Morris D.L., Legator M.S., and Abdel-Rahman S.Z. Response to comments on 'Cytogenetic effects in children treated with methylphenidate' by El-Zein et al. Cancer Lett. 231 January (1) (2006) 146-148 (Cancer Lett. 231, 2006, 146-148)
10. Fenech M., Chang W.P., Kirsch-Volders M., Holland N., Bonassi S., and Zeiger E. HUMN project: detailed description of the scoring criteria for the cytokinesis-block micronucleus assay using isolated human lymphocyte cultures. Mutat. Res. 534 (2003) 65-75
11. Hiroi T., Imaoka S., and Funae Y. Dopamine formation from tyramine by CYP2D6. Biochem. Biophys. Res. Commun. 249 (1998) 838-843
12. Holland N., Bolognesi C., Kirsch-Volders M., Bonassi S., Zeiger E., Knasmueller S., and Fenech M. The micronucleus assay in human buccal cells as a tool for biomonitoring DNA damage: the HUMN project perspective on current status and knowledge gaps. Mutat. Res. (2008) (Epub ahead of print)
13. Holtmann M., Kaina B., and Poustka F. Methylphenidate-induced cytogenetic alterations? (in German). Z. Kinder. Jugendpsychiatr. Psychother. 34 (2006) 215-220
14. Jacobsen-Kram D., Mattison D., Shelby M., Slikker W., Tice R., and Witt K. Letter to the editor. Cancer Lett. 260 (2008) 216-218
15. Janhsen K. In: Glaeske G., and Janhsen K. (Eds). GEK-Arzneimittel-Report 2007 (2007), Asgard-Verlag, ST. Augustin/Germany 226-244
16. Kaufman J., Birmaher B., Brent D., Rao U., Flynn C., Moreci P., et al. Schedule for affective disorders and schizophrenia for school-age children-present and lifetime version (K-SADS-PL): initial reliability and validity data. J. Am. Acad. Child Adolesc. Psychiatry 36 (1997) 980-988
17. Neri M., Ceppi M., Knudsen L.E., Merlo D.F., Barale R., Puntoni R., and Bonassi S. Baseline micronuclei frequency in children: estimates from meta- and pooled analyses. Environ. Health Perspect. 113 (2005) 1226-1229
18. Oestreicher N., Friedman G.D., Jiang S.F., Chan J., Quesenberry Jr. C., and Habel L.A. Methylphenidate use in children and risk of cancer at 18 sites: results of surveillance analyses. Pharmacoepidemiol. Drug Safety 16 (2007) 1268-1272
19. Preston R.J., Kollins S.H., Swanson J.M., Greenhill L.L., Wigal T., Elliott G.R., and Vitiello B. Comments on 'Cytogenetic effects in children treated with methylphenidate' by El-Zein et al. Cancer Lett. 230 (2005) 292-294
20. Romanos M., Renner T.J., Schecklmann M., Hummel B., Roos M., von Mering C., Pauli P., Reichmann H., Warnke A., and Gerlach M. Improved odor sensitivity in attention-deficit/hyperactivity disorder. Biol. Psychiatry 64 (2008) 938-940
21. Selby J.V., Friedman G.D., and Fireman B.H. Screening prescription drugs for possible carcinogenicity: 11 to 15 years of follow-up. Cancer Res. 49 (1989) 5736-5747
22. Stopper H., Walitza S., Warnke A., and Gerlach M. Brief review of available evidence concerning the potential induction of genomic damage by methylphenidate. J. Neural Transm. 115 (2008) 331-334
23. Stiensmeier-Pelster J., Schurmann M., and Duda K. Depressions-Inventar für Kinder und Jugendliche (DIKJ). 2nd rev. ed. (2000), Hogrefe, Goettingen
24. Suter W., Martus H.J., and Elhajouji A. Methylphenidate is not clastogenic in cultured human lymphocytes and in the mouse bone-marrow micronucleus test. Mutat. Res. 607 (2006) 153-159
25. Taylor E., Döpfner M., Sergeant J., Asherson P., Banaschewski T., Buitelaar J., Coghill D., Danckaerts M., Rothenberger A., Sonuga-Barke E., Steinhausen H.C., and Zuddas A. European clinical guidelines for hyperkinetic disorder-first upgrade. Eur. Child Adolesc. Psychiatry 13 (2004) I7-30
26. Thomas P., Harvey S., Gruner T., and Fenech M. The buccal cytome and micronucleus frequency is substantially altered in Down's syndrome and normal ageing compared to young healthy controls. Mutat. Res. 638 (2008) 37-47
27. Walitza S., Werner B., Romanos M., Warnke A., Gerlach M., and Stopper H. Does methylphenidate cause a cytogenetic effect in children with attention deficit hyperactivity disorder?. Environ. Health Perspect. 115 (2007) 936-940